A Single-center, Double-blind, Parallel-group, Randomized, Placebo-controlled, Multiple-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-709478 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2019
At a glance
- Drugs ACT 709478 (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
- 02 Jan 2019 Status changed from recruiting to completed.
- 01 Nov 2018 Planned End Date changed from 30 Sep 2018 to 14 Nov 2018.
- 01 Nov 2018 Planned primary completion date changed from 30 Sep 2018 to 14 Nov 2018.